Alicia Morgans, MD, MPH

Alicia Morgans is a Genitourinary Medical Oncologist and the Director of the Survivorship Program at Dana-Farber Cancer Institute. A clinician and investigator, she has expertise in clinical trials and patient-reported outcome measures, as well as incorporating patient preferences and beliefs into clinical decision-making. Her research has investigated complications of systemic therapy for prostate cancer survivors, including the study of skeletal, cardiovascular, diabetic, and cognitive complications. Her work has been funded by grants from the Prostate Cancer Foundation, the Department of Defense, the National Comprehensive Cancer Network, and the Rising Tide Foundation, among others. She is a member of the advanced and localized prostate cancer treatment guidelines committee of the American Urologic Association, the metastatic prostate cancer guidelines for the American Society of Clinical Oncology,  and was previously a member of the cardio-oncology committee of the American Heart Association. Between 2016 and 2025, she served as President of the Medical Advisory Board for ZERO, a non-profit organization dedicated to supporting education and research funding for prostate cancer research, and she continues as a member and advocate.